Suven Life Science gets nod to enhance investment limits in USA subsidiary

15 Apr 2019 Evaluate

Suven Life Science’s board has approved the enhancement of investment limits in wholly owned subsidiary (WOS) in USA Suven Neurosciences, Inc. from $25 million upto $50 million to undertake clinical trials on the molecules in the pipeline. The Board of directors of the company at its meeting held on April 15, 2019 has approved for the same.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets.

Suven Life Sciences Share Price

133.50 -3.40 (-2.48%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×